TP53 and B-cell chronic lymphocytic leukemia: Interestingly, the proportion of clonal B-cells carrying del17p (TP53) among the three cases found to have this alteration (all of them with stable CLL clones) was highly variable: 7%, 58%, and 98%, suggesting that its predictive value for TFT might be independent from the tumor cell kinetics.